{"id":"placebo-for-ustekinumab","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to natural disease progression, regression to the mean, or the placebo effect (psychological/expectation-based response). In this context, it serves as the control arm in a Phase 3 trial of ustekinumab.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:29.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial of ustekinumab (active comparator)"}]},"trialDetails":[{"nctId":"NCT06934226","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-04-15","conditions":"Plaque Psoriasis","enrollment":752},{"nctId":"NCT05327790","phase":"PHASE2","title":"LFMT vs Placebo in New Biologic Start for Ulcerative Colitis","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-06-03","conditions":"Ulcerative Colitis","enrollment":40},{"nctId":"NCT03370133","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-12-06","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis","enrollment":567},{"nctId":"NCT04572815","phase":"PHASE2","title":"Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-14","conditions":"Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm","enrollment":116},{"nctId":"NCT04232553","phase":"PHASE3","title":"A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-22","conditions":"Crohn's Disease","enrollment":996},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT04978493","phase":"PHASE2","title":"A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-02","conditions":"Crohn Disease","enrollment":49},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02877134","phase":"PHASE2","title":"Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-25","conditions":"Crohn Disease","enrollment":388},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT04882072","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-09-15","conditions":"Takayasu Arteritis","enrollment":14},{"nctId":"NCT04305327","phase":"PHASE3","title":"Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2022-12-07","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT04533737","phase":"PHASE4","title":"Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2020-12-17","conditions":"Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis","enrollment":113},{"nctId":"NCT02319759","phase":"PHASE2","title":"Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-03-27","conditions":"Psoriatic Arthritis","enrollment":149},{"nctId":"NCT03926130","phase":"PHASE3","title":"A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-07-23","conditions":"Crohn's Disease","enrollment":1158},{"nctId":"NCT04245215","phase":"PHASE3","title":"Loss of RESponse to Ustekinumab Treated by Dose Escalation","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2020-03-11","conditions":"Crohn Disease","enrollment":108},{"nctId":"NCT02684357","phase":"PHASE3","title":"BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":577},{"nctId":"NCT02684370","phase":"PHASE3","title":"BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02","conditions":"Psoriasis","enrollment":560},{"nctId":"NCT02561806","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10","conditions":"Plaque Psoriasis","enrollment":302},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT02187172","phase":"PHASE4","title":"Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-07","conditions":"Psoriasis, Cardiovascular Disease","enrollment":43},{"nctId":"NCT01999868","phase":"PHASE2","title":"Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-19","conditions":"Psoriasis","enrollment":108},{"nctId":"NCT01806662","phase":"PHASE2","title":"Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2013-03","conditions":"Atopic Dermatitis","enrollment":32},{"nctId":"NCT02203032","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10-07","conditions":"Psoriasis","enrollment":872},{"nctId":"NCT01369342","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-07","conditions":"Crohn's Disease, Inflammatory Bowel Disease, IBD","enrollment":640},{"nctId":"NCT01369329","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-07","conditions":"Crohn's Disease, IBD, Colitis","enrollment":769},{"nctId":"NCT01389973","phase":"PHASE2","title":"A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Primary Biliary Cirrhosis","enrollment":20},{"nctId":"NCT01645280","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08","conditions":"Arthritis, Rheumatoid","enrollment":274},{"nctId":"NCT01945086","phase":"PHASE2","title":"A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-09","conditions":"Dermatitis, Atopic","enrollment":79},{"nctId":"NCT01009086","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-12","conditions":"Arthritis, Psoriatic","enrollment":615},{"nctId":"NCT01077362","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03","conditions":"Arthritis, Psoriatic","enrollment":312},{"nctId":"NCT00265122","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2004-04","conditions":"Crohn Disease","enrollment":131},{"nctId":"NCT00267969","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-12","conditions":"Psoriasis","enrollment":766},{"nctId":"NCT00307437","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-05","conditions":"Psoriasis","enrollment":1230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":385,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Ustekinumab","genericName":"Placebo for Ustekinumab","companyName":"Janssen Scientific Affairs, LLC","companyId":"janssen-scientific-affairs-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial of ustekinumab (active comparator).","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}